Genmab | GEN - Operating Expenses


Genmab reported DKK748M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Almirall EUR 531.16M 13.76M Jun/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 11.69B 6.9B Jun/2026
argenx SE USD 1.02B 118M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bayer EUR 10.04B 168M Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Demant DKK 10.79B 1.16B Jun/2026
Exelixis USD 380.28M 20.8M Jun/2026
Fresenius Medical Care EUR 4.32B 20.7M Jun/2026
Genmab DKK 748M 77M Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
GN Store Nord DKK 2.11B 51M Jun/2026
GRIFOLS EUR 1.55B 94M Jun/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Insmed USD 526.79M 20.55M Jun/2026
Lakefront Biotherapeutics EUR 55.62M 14.56M Jun/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.34B 249M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
UCB EUR 2.96B 196M Dec/2025